Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy

Sooft Italia

Status: Withdrawn

Conditions: Primary Open Angle Glaucoma; Intraocular Pressure

Study type: Observational

Funder types: Industry

Identifiers

NCT00864578

KRONEK-MTMT

KRONEK-001

Details and patient eligibility

About

Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients. However, some patients cannot reach the target pressure despite a multitherapy with a combination of drugs, and are therefore addressed to surgical treatments. Forskolin is a natural compound that is a receptor-independent adenyl-cyclase activator, that increases intracellular cAMP. It has been shown to be able to decrease IOP after topical application, by a mechanism that is not used by the other drugs. Aim of the present study is to see whether a food supplement containing forskolin (KRONEK) has any effect on the IOP of POAG patients that cannot reach their target pressure, and are therefore on the waiting list for surgical intervention.

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 30-70 Years
• Sex: both
• Pathology: POAG
• Characteristics: Target pressure not achieved with current treatments

Exclusion criteria

• Concomitant ocular pathologies
• Previous ocular surgery
• Known hypersensitivity to any of the components in the KRONEK tablets
• Concomitant participation in other trials